| Title |
Interferon-free combination therapies for the treatment of hepatitis C: current insights
|
|---|---|
| Published in |
Hepatic medicine evidence and research, November 2015
|
| DOI | 10.2147/hmer.s55864 |
| Pubmed ID | |
| Authors |
Jacinta A Holmes, Alexander J Thompson |
| Abstract |
The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years. The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens. There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication. This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 19% |
| Student > Bachelor | 9 | 17% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Researcher | 3 | 6% |
| Other | 11 | 20% |
| Unknown | 12 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 33% |
| Agricultural and Biological Sciences | 5 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Immunology and Microbiology | 3 | 6% |
| Computer Science | 2 | 4% |
| Other | 10 | 19% |
| Unknown | 13 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2015.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from Hepatic medicine evidence and research
#100
of 116 outputs
Outputs of similar age
#252,307
of 294,815 outputs
Outputs of similar age from Hepatic medicine evidence and research
#2
of 2 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 116 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,815 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.